Atria Investments Inc Raises Stock Holdings in Certara, Inc. (NASDAQ:CERT)

Atria Investments Inc raised its holdings in Certara, Inc. (NASDAQ:CERT) by 21.6% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 19,743 shares of the company’s stock after purchasing an additional 3,501 shares during the period. Atria Investments Inc’s holdings in Certara were worth $231,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. The Manufacturers Life Insurance Company raised its position in shares of Certara by 4.5% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 22,871 shares of the company’s stock worth $317,000 after purchasing an additional 975 shares during the last quarter. Russell Investments Group Ltd. lifted its position in shares of Certara by 1.6% in the first quarter. Russell Investments Group Ltd. now owns 77,753 shares of the company’s stock valued at $1,375,000 after acquiring an additional 1,191 shares in the last quarter. Louisiana State Employees Retirement System boosted its stake in shares of Certara by 2.3% in the second quarter. Louisiana State Employees Retirement System now owns 54,200 shares of the company’s stock worth $751,000 after acquiring an additional 1,200 shares during the last quarter. Blue Trust Inc. purchased a new stake in shares of Certara during the second quarter worth approximately $26,000. Finally, Innealta Capital LLC acquired a new position in Certara in the 2nd quarter valued at $36,000. 73.96% of the stock is currently owned by hedge funds and other institutional investors.

Certara Price Performance

Shares of CERT stock opened at $10.36 on Friday. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.86 and a quick ratio of 2.86. The company has a market capitalization of $1.67 billion, a PE ratio of -51.80, a price-to-earnings-growth ratio of 4.94 and a beta of 1.51. The firm’s 50-day moving average is $10.79 and its two-hundred day moving average is $13.19. Certara, Inc. has a 12 month low of $9.41 and a 12 month high of $19.87.

Certara (NASDAQ:CERT) last released its quarterly earnings results on Wednesday, November 6th. The company reported $0.13 EPS for the quarter, beating the consensus estimate of $0.11 by $0.02. The firm had revenue of $94.80 million for the quarter, compared to analyst estimates of $95.51 million. Certara had a negative net margin of 8.34% and a positive return on equity of 3.43%. The business’s revenue for the quarter was up 10.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.06 EPS. Analysts predict that Certara, Inc. will post 0.28 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages have issued reports on CERT. Barclays lowered their target price on shares of Certara from $14.00 to $12.00 and set an “equal weight” rating on the stock in a research note on Thursday, November 7th. Robert W. Baird lowered their price target on shares of Certara from $18.00 to $13.00 and set a “neutral” rating on the stock in a research report on Tuesday, November 5th. Finally, UBS Group upgraded shares of Certara from a “neutral” rating to a “buy” rating and set a $16.00 price objective for the company in a report on Friday, September 27th. Six research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $15.92.

Insider Activity

In other news, insider Patrick F. Smith sold 5,409 shares of Certara stock in a transaction on Monday, October 7th. The stock was sold at an average price of $11.03, for a total value of $59,661.27. Following the completion of the sale, the insider now directly owns 50,091 shares of the company’s stock, valued at approximately $552,503.73. The trade was a 9.75 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Leif E. Pedersen sold 51,224 shares of the stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $11.29, for a total value of $578,318.96. Following the transaction, the insider now directly owns 99,704 shares in the company, valued at approximately $1,125,658.16. The trade was a 33.94 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 2.39% of the company’s stock.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.